Navigation Links
Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Date:3/19/2008

vanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam, President and CEO Tel: +41-61-417-96-60

Harry Welten, MBA, CFO and Senior Vice President Tel: +41-61-417-96-65

Paul Verbraeken, Head of Corporate Communications Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Announces Full Year 2007 Financial Results
2. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
3. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
4. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
5. Arpida-Supported CME Symposium Available Online
6. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
7. Arpida Presents Preclinical Data on AR-2474 at ICAAC
8. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
9. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
10. Arpida Interim Results for six Months to 30 June 2007
11. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Today the Academy of Model Aeronautics (AMA) ... of Appeals for the D.C. Circuit challenging the FAA’s Interpretation ... Federal Register on June 25, 2014. , The AMA ... text and intent of the FAA Modernization and Reform Act ... on any new rules or regulations regarding model aircraft that ...
(Date:8/22/2014)... direct observations of how facets form and develop ... sophisticated and effective nanocrystal design and reveal that ... growth breaks down at the nanoscale. , Researchers ... Berkeley National Laboratory (Berkeley Lab) used highly sophisticated ... camera to capture the physical mechanisms that ...
(Date:8/22/2014)... 2014 Research and Markets has ... Gel Permeation Chromatography (GPC) Industry Report 2014" report ... China Gel Permeation Chromatography (GPC) Industry Report is a ... the global gel permeation chromatography industry with a focus ... basic overview of the industry including definitions, classifications, applications ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 The ... model organisms can be accelerated by exome sequencing. ... manufacturing technologies, the custom SeqCap EZ Developer system ... , Mr. Watson will additionally present how he ... commercially available human and mouse exome kits. With ...
Breaking Biology Technology:AMA Files Petition for Review of FAA’s Interpretive Rule 2Shaping the future of nanocrystals 2Shaping the future of nanocrystals 3Shaping the future of nanocrystals 4Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2
... Cedara Software said it has acquired through ... medical software company in Paris. Cedara is he Toronto-based ... information technology company headquartered in Milwaukee. , ,It will ... managment, which has been installed in 25 French facilities. ...
... revenues for the quarter ended December 31 were up 18 ... quarter, compared to $1.6 million a year ago. , ,A ... this year and projected cashflow break-even sometime in the next ... net loss was $1.6 million for the quarter, compared to ...
... Fifty-two University of Wisconsin undergrads are going to ... Thursday and Friday for creative inventions that could turn ... for Creativity and Tong Prototype Prize reward students for ... At this year's Innovation Days, undergrads will show off ...
Cached Biology Technology:
(Date:8/21/2014)... international standards process, will be available soon and will ... published in the OnlineFirst version of Nutrition in ... of the American Society for Parenteral and Enteral Nutrition ... of misconnection that can be harmful and even fatal ... join medical devices, components, and accessories to deliver fluids ...
(Date:8/21/2014)... have developed a novel and versatile modeling strategy to ... new materials as well as for studying polyelectrolytes, including ... to model much larger and more complex polyelectrolyte systems, ... Li, lead author of a paper on the work ... Materials Science and Engineering. "This is a big step ...
(Date:8/20/2014)... a study of 158 pregnant teenagers in Rochester, NY, ... intentional consumption of ice, cornstarch, vacuum dust, baby powder ... Cornell study. , Moreover, such teens had significantly lower ... eat nonfood substances. , Pregnant teens, regardless of pica, ... lead to iron deficiency and anemia. Low iron in ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2Pica in pregnant teens linked to low iron 2
... High-intensity focused ultrasound emitted in short pulses is ... to cancerous cells without destroying healthy tissue, according ... the journal Radiology. , High-intensity focused ultrasound (HIFU) ... destroy tumors through long and continuous exposures that ...
... grow these cells are costly and don't produce cells ... embryonic stem cells, said Shang-Tian Yang, a professor of ... Federal rules forbid the federal funding of research on ... the National Institutes of Health's Human Embryonic Stem Cell ...
... of the NIH public access policy announced earlier this ... , BioMed Central welcomes the announcement of the ... The NIH calls on all of its grantees to deposit ... of Medicine's PubMed Central and make them freely available within ...
Cached Biology News:Pulsating ultrasound enhances gene therapy for tumors 2Researchers devise way to mass-produce embryonic stem cells 2Researchers devise way to mass-produce embryonic stem cells 3BioMed Central welcomes the new National Institutes of Health public access policy 2
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
Phospho- (Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb...
Component in MasterPure™ Purification Kits...
Chlamydia pneumoniae (TWAR)...
Biology Products: